Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol ...

Gilead Sciences easily beat third-quarter forecasts late Wednesday, and raised its outlook in a move that could bolster ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Gilead’s HIV sector, populated by dominant HIV treatment Biktarvy and PrEP Descovy, contributed $5.1 billion to the company’s total quarterly sales haul of $7.5 billion, reflecting growth of 7 ...

November 06, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the ...

Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial ...